Itamar Medical’s WatchPAT 300 is a Simple and Reliable Home Sleep Apnea Detection System

Israel-based Itamar Medical launched WatchPAT 300.

Healthcare

Cardiology

Technology

Image: Itamar Medical

Caesarea, Israel-based Itamar Medical launched WatchPAT 300, the next generation WatchPAT system for home sleep apnea testing. New developments in the WatchPAT 300 are designed to enhance both patients’ experience as well as provide physicians with a trusted and cost-effective method for rapid, scalable and effective diagnosis of sleep apnea.

The U.S. Food and Drug Administration (FDA) gave clearance to WatchPAT 300 on August 17, 2018 and the system will gradually replace the current WatchPAT 200 platform, reports press release.

“Sleep apnea has reached epidemic levels and is estimated to affect 25 percent of adults worldwide,” said Gilad Glick, President and CEO of Itamar Medical. “This has significant health and economic implications, as half of all patients with cardiovascular disease are believed to suffer from sleep apnea and the total cost of unmanaged obstructive sleep apnea is $150 billion each year in the United States alone. Addressing the challenge of efficiently and cost-effectively diagnosing the millions of patients with undiagnosed sleep apnea requires a simple, accurate and scalable modality. We believe that WatchPAT 300 – which demonstrates Itamar Medical’s continued commitment to innovation focused on meeting the needs of patients, health systems, payers and physicians – can play a critical role in solving this challenge.”

*Itamar Medical’s EndoPAT system is an FDA-approved device to test endothelial dysfunction and to evaluate the risk of heart disease and other cardiovascular diseases (Image: Itamar Medical)*

The intuitively designed WatchPAT system is easy to use and removes the need for cumbersome nasal canula or chest belts. It is based on the peripheral arterial tone signal (PAT) and uses its advanced actigraphy to differentiate between wake and sleep periods to calculate true sleep time. PAT amplitude and pulse rate is used to differentiate between non-rapid eye movement (REM) and REM sleep. It also provides clinically validated sleep architecture, based on sleep stages, including sleep efficiency, sleep latency and REM latency. Its total sleep time reduces the risk of misdiagnosis and misclassification that has been reported to be 20 percent in studies using total recording time.

The WatchPAT 300 will be showcased at SLEEP 2019 on June 8-12 in San Antonio, Texas.

Itamar Medical develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea with a focus on the cardiology market. The company’s EndoPAT™ system is an FDA-approved device to test endothelial dysfunction and to evaluate the risk of heart disease and other cardiovascular diseases.

‍